Loading quotes...
Forecast
The analysts' average price target is €33.97 (+11.96%). The median is €33.97 (+11.96%).
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -298.79k | - |
| Net profit | -17.41m | - |
| EBITDA | -18.95m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €964m |
Number of shares | 33.45m |
52-week high/low | €30.25 - €15.25 |
| Dividends | No |
Beta | -0.89 |
P/E ratio | -19.42 |
PEG ratio | 0.14 |
P/B ratio | 4.64 |
P/S ratio | 0.00 |
Company profile
| Name | SpyGlass Pharma Inc |
| CEO | Patrick H. Mooney |
| Employees | 76 |
